198 related articles for article (PubMed ID: 25602792)
1. Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma.
Udager AM; Pan J; Magers MJ; Palapattu GS; Morgan TM; Montgomery JS; Weizer AZ; Hafez KS; Miller DC; Wolf JS; McHugh JB; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Am J Surg Pathol; 2015 Apr; 39(4):549-57. PubMed ID: 25602792
[TBL] [Abstract][Full Text] [Related]
2. BRAF mutations in metanephric adenoma of the kidney.
Choueiri TK; Cheville J; Palescandolo E; Fay AP; Kantoff PW; Atkins MB; McKenney JK; Brown V; Lampron ME; Zhou M; Hirsch MS; Signoretti S
Eur Urol; 2012 Nov; 62(5):917-22. PubMed ID: 22727996
[TBL] [Abstract][Full Text] [Related]
3. [Molecular features of metanephric adenoma and their values in differential diagnosis].
Wang X; Shi SS; Yang WR; Ye SB; Li R; Ma HH; Zhang RS; Lu ZF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):38-42. PubMed ID: 28072975
[No Abstract] [Full Text] [Related]
4. BRAF exon 15 mutations in pediatric renal stromal tumors: prevalence in metanephric stromal tumors.
Marsden L; Jennings LJ; Gadd S; Yu M; Perlman EJ; Cajaiba MM
Hum Pathol; 2017 Feb; 60():32-36. PubMed ID: 27769870
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutations in pediatric metanephric tumors.
Chami R; Yin M; Marrano P; Teerapakpinyo C; Shuangshoti S; Thorner PS
Hum Pathol; 2015 Aug; 46(8):1153-61. PubMed ID: 26014474
[TBL] [Abstract][Full Text] [Related]
6. KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas.
Catic A; Kurtovic-Kozaric A; Sophian A; Mazur L; Skenderi F; Hes O; Rohan S; Rakheja D; Kogan J; Pins MR
BMC Med Genet; 2020 Oct; 21(1):202. PubMed ID: 33046021
[TBL] [Abstract][Full Text] [Related]
7. Metanephric Adenoma-Epithelial Wilms Tumor Overlap Lesions: An Analysis of BRAF Status.
Wobker SE; Matoso A; Pratilas CA; Mangray S; Zheng G; Lin MT; Debeljak M; Epstein JI; Argani P
Am J Surg Pathol; 2019 Sep; 43(9):1157-1169. PubMed ID: 31192863
[TBL] [Abstract][Full Text] [Related]
8. Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases.
Ding Y; Wang C; Li X; Jiang Y; Mei P; Huang W; Song G; Wang J; Ping G; Hu R; Miao C; He X; Chen G; Li H; Zhu Y; Zhang Z
Diagn Pathol; 2018 Aug; 13(1):54. PubMed ID: 30111351
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution.
Chan E; Stohr BA; Croom NA; Cho SJ; Garg K; Troxell ML; Higgins JP; Bean GR
Histopathology; 2020 Jun; 76(7):1084-1090. PubMed ID: 32064677
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological features of adult Wilms tumor with BRAF V600E mutation].
Gan HL; Wang QF; Zhu XL; Lyu H; Wang J
Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1210-1215. PubMed ID: 38058036
[No Abstract] [Full Text] [Related]
11. Frequent BRAF V600E Mutations in Metanephric Stromal Tumor.
Argani P; Lee J; Netto GJ; Zheng G; Tseh-Lin M; Park BH
Am J Surg Pathol; 2016 May; 40(5):719-22. PubMed ID: 26796506
[No Abstract] [Full Text] [Related]
12. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
[TBL] [Abstract][Full Text] [Related]
13. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
[TBL] [Abstract][Full Text] [Related]
14. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization of Metanephric Adenoma, Epithelial Wilms Tumor, and Overlap Lesions: An Integrated Whole-exome and Transcriptome Sequencing Analysis.
Pan CC; Tseng CE; Kuroda N; Yano M; Yasuda M; Nagashima Y; Yeh YC; Wang YC; Chang YH; Epstein JI
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):257-263. PubMed ID: 35384875
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
20. Paediatric metanephric tumours: a clinicopathological and molecular characterisation.
de Jel DVC; Hol JA; Ooms AHAG; de Krijger RR; Jongmans MCJ; Littooij AS; Drost J; van Grotel M; van den Heuvel-Eibrink MM
Crit Rev Oncol Hematol; 2020 Jun; 150():102970. PubMed ID: 32371339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
